Recursion

The models and the data flywheel are the company rather than a capability inside it. The Recursion OS learns from cellular imaging and multiomic data generated by the company's own high throughput experimentation, and the entire operating structure exists to feed it, including BioHive-2, described at completion as the fastest supercomputer wholly owned and operated by any pharmaceutical company, built with NVIDIA technology. The Exscientia combination added generative chemistry design and automated synthesis, extending model driven decision making from target biology through molecule design. Removing the models does not leave a lesser product, it leaves no product.

The oversight mechanism is structural and reasonably strong: model hypotheses are tested against wet lab experimentation at industrial scale, so predictions meet physical evidence continuously rather than accumulating unchecked. Human strategic judgment is also demonstrably in the loop, as the May 2025 decision to deprioritize three clinical stage programs shows leadership overriding platform momentum. Held at B because no disclosure was located on how candidate selection is gated between model output and committed spend, meaning the specific human decision points are inferred from company behaviour rather than documented.

Named systems and disclosed infrastructure put this above the opaque end of the category: the Recursion OS, the Phenom family of foundation models, BioHive-2 and a stated data corpus of more than 60 petabytes generated in house or licensed from partners including Helix and Tempus. Held at B rather than A because no peer reviewed methods paper establishing core platform performance was located in this review, so the headline capability claims rest on company communications. Widely circulated specific figures for model accuracy and patent counts trace to secondary commentary rather than to primary company or peer reviewed sources and should not be relied upon in diligence.

Genuinely mixed, and the mix is the useful signal. On the positive side, pharma partners have paid: more than 450 million dollars in upfront and realized milestone payments received against a disclosed potential exceeding 20 billion dollars, which is third party validation of delivered work rather than a vendor assertion, and multiple programs reached the clinic. On the negative side, the company promised roughly ten clinical readouts within eighteen months at the time of the Exscientia combination, then in May 2025 deprioritized three clinical stage programs, paused a fourth and wound down a preclinical program, narrowing to six active projects. That attrition is the honest counterweight to platform scale claims, and it is exactly the evidence a buyer evaluating industrialized discovery should weigh. No approved medicine has yet emerged from the platform.

Unlike pure chemistry platforms this axis genuinely applies, which is why it is graded rather than marked not applicable. The disclosed data corpus includes material licensed from Helix and Tempus, both of which hold human genomic and clinical data, so human derived data flows into the platform. No published disclosure was located covering consent provenance for that licensed data, de identification standard, permitted secondary use, or what happens to derived model representations if a licensing relationship ends. The distinction matters for comparison within this category: a platform training on human data carries stewardship obligations that a platform training on molecular structures does not, and the disclosure here does not yet match the obligation.

Not applicable in the direct sense. Counterparties are pharmaceutical partners and data licensors rather than covered entities transferring protected health information under a business associate agreement, so the governing instruments are commercial data licences. Note that this places the consent and permitted use questions raised on the stewardship axis inside private contracts rather than inside a disclosed compliance framework.

No SOC 2, ISO 27001 or equivalent attestation was located and no trust center was found. Given that the platform ingests licensed human genomic and clinical data alongside partners' proprietary target information, this is a more material gap here than for peers handling molecular data only.

Correctly structured: the discovery platform is not a regulated device, and regulatory standing sits at the asset level where multiple programs have reached clinical stage across oncology and rare disease under active INDs. No approval has been obtained. Buyers should read the 2025 pipeline reprioritization as a reminder that clinical stage status is not durable, since three clinical stage programs were deprioritized in a single quarter.

No AI governance framework or bias disclosure was located. The domain relevant question for a phenomics platform is biological representativeness rather than demographic fairness in the clinical sense: cellular models carry the genetic background of their donors, and a morphology model trained predominantly on cell lines from narrow ancestral backgrounds may generalize unevenly to patient populations that differ from them. With human genomic data also licensed into the corpus, cohort composition becomes a second and compounding representativeness question. Neither appears addressed publicly.

Not applicable. This is a preclinical discovery platform with no provider workflow surface and no EHR touchpoint. Data integration effort is directed at internal experimental pipelines and licensed external datasets rather than at clinical systems.

Not applicable in the software sense. The Recursion OS is an internal operating platform rather than a product deployed into a customer environment, and the commercial relationship is discovery partnership rather than licensing, so questions of tenancy, hosting and residency do not arise for a counterparty. A partner's data protection question is therefore contractual, covering what the partner contributes and what the platform retains, rather than architectural.

Unusually specific, and public listing is the reason. As a Nasdaq registrant (RXRX) the company discloses partnership economics with real numbers rather than adjectives: approximately 200 million dollars in expected milestone payments over 24 months at the time of the Exscientia combination, more than 20 billion dollars in total potential milestones before royalties, more than 450 million dollars already received, and approximately 850 million dollars in combined cash. Pipeline changes including deprioritizations are announced through quarterly results rather than allowed to disappear quietly, which is the harder half of transparency.

Deliberately narrowed rather than broad. Following the May 2025 prioritization the internal pipeline runs six active development programs, four in oncology and two in rare disease, with the company describing these as its consistent focus. The underlying platform is claimed to work across biology generally and the partnership portfolio extends further, but the demonstrated internal application is concentrated. Buyers outside oncology and rare disease should treat applicability as a partnership discussion rather than a proven setting.